We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score 7. At 12 weeks, response was achieved by 79.5% of the patients (n 35) and remission by 36.4% of patients (n 16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.
APA (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn.American Psychiatric Association, Washington DC
2.
Ballenger J C (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry60: 29-34
3.
Chung M Y, Min K H, Jun Y J, Kim S S, Kim W C, Jun E M (2004) Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol19: 489-494
4.
Connor K M, Davidson J R, Weisler R H, Ahearn E (1999). A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol14: 29-31
5.
Davidson J R, Weisler R H, Butterfield M I, Casat C D, Connor K M, Barnett S, van Meter S (2003) Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry15: 188-191
6.
de Boer T (1995) The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol10: 19-23
7.
Fava M (2000) Weight gain and antidepressants. J Clin Psychiatry61: 37-41
8.
Fava M, Dunner D L, Greist J H, Preskorn S H, Trivedi M H, Zajecka J, Cohen M (2001) Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry6: 413-420
9.
First M B, Spitzer R L, Gibbon M, Williams J B (1997) Structured clinical interview for DSM-IV axis I disorder-outpatient Edition (SCID-I/OP, Version 2.0, 4/97 revision). New York State Psychiatric Institute: Bio-metrics Research Department
10.
Goodnick P J, Puig A, DeVane C L, Freund B V (1999) Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry60: 446-448
11.
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology Revised. Rockville, MD: National Institute for Mental Health, Psychopharmacology Research Branch (pp. 217-222) 313-331
12.
Hackett D, Haudiquet V, Salinas E (2003) A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry18: 182-187. DOI:10.1016/S0924-9338(03)00046-4
13.
Hamilton M (1959) The assessment of anxiety states by rating. Br J Psychiatry32: 50-55
14.
Montgomery S A, Asberg M A (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382-389
15.
Ribeiro L, Busnello J V, Kauer-Sant’Anna M, Madruga M, Quevedo J, Busnello E A, Kapczinski F (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res34: 1303-1307
16.
Rickels K, Downing R, Schweizer E, Hassman H (1993) Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry50: 884-895
17.
Roose S P, Nelson J C, Salzman C, Hollander S B, Rodrigues H (2003). Mirtazapine in the Nursing Home Study Group: open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin19: 737-746. DOI:10.1185/030079903125002441
18.
Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G (2003) Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol18: 35-38
19.
Sheehan D V, Harnet Sheehan K, Raj B A (1996) The measurement of disability. Int Clin Psychopharmacol11: 89-95
20.
Sitsen J M A, Moors J (1994) Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Drug Invest8: 339-344
21.
Snaith R P, Taylor C M (1985). Irritability: definition, assessment and associated factors. Br J Psychiatry147: 127
22.
Thase M E, Nierenberg A A, Keller M B, Panagides J; Relapse Prevention Study Group (2001) Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry62: 782-788
23.
Thyer B A (1992) Clinical Anxiety Scale (CAS). In: Hudson W W (ed.), The WALMYR Assessment Scale Scoring Manual. WALMYR Publishing,
24.
Temple, AZVan Veen J F, Van Vliet I M, Westenberg H G (2002) Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol17: 315-317
25.
Wittchen H U, Carter R M, Pfister H, Montgomery S A, Kessler R C (2000) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol15: 319-328
